The antifibrotic activity of pirfenidone in preclinical models of pulmonary fibrosis. a) Experimental design and effects of prophylactic pirfenidone treatment.

Slides:

Advertisements

Similar presentations

Wound repair in healthy lungs and IPF

Advertisements

Immune mediators of tissue remodelling and lung function impairment in tuberculosis. Immune mediators of tissue remodelling and lung function impairment.

Wound repair in healthy lungs and IPF

Effects of a caspase-1 inhibitor and NLRP3 inhibitor on nontypeable Haemophilus influenzae (NTHi)-induced interleukin (IL)-1β production. a) Peripheral.

Pathological alterations in idiopathic pulmonary fibrosis (IPF).

Flow diagram of the systematic research method for detecting matching microRNAs (miRNAs) in systemic sclerosis (SSc) and idiopathic pulmonary fibrosis.

Kaplan–Meier curve for the time until the development of lung cancer in patients with idiopathic pulmonary fibrosis. Kaplan–Meier curve for the time until.

Representative images of immunohistochemical staining of discoidin domain receptor (DDR)2 in interstitial lung disease (ILD) other than idiopathic pulmonary.

Co-occurrence network between taxa and biomarkers.

Colocalisation of NLRP3 specks with cleaved interleukin (IL)-1β in bronchoalveolar lavage (BAL) macrophages, and nontypeable Haemophilus influenzae (NTHi)-stimulated.

In chronic haemorrhage a) several pigmented macrophages fill the alveoli with dense fibrosis of the interstitium; b) the haemosiderin pigment in macrophages.

Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best supportive care.

High-resolution chest computed tomography images of a patient with lymphangioleiomyomatosis, showing round-shaped, thin-walled cysts distributed diffusely.

The key pathological mechanisms underlying vascular changes in pulmonary hypertension (PH). The key pathological mechanisms underlying vascular changes.

Representative photomicrograph of small airways abnormalities in a subject with chronic obstructive pulmonary disease. Representative photomicrograph of.

Axial computed tomography (CT) images a) at baseline and b) at a 12-month follow-up scan, in a patient with idiopathic pulmonary fibrosis (IPF). b) Note.

Histological evidence of alveolar epithelial cells undergoing epithelial-mesenchymal transition in response to transforming growth factor-β1. a–c) α-smooth.

Schematic representation of the current evidence for the association of cadmium exposure with smoking-related lung disease including chronic obstructive.

Serial computed tomography (CT) imaging for monitoring disease progression in patients with idiopathic pulmonary fibrosis. Serial computed tomography (CT)

Electromagnetic navigation image: the icon representing the locatable guide (arrow) can be seen 3 mm away from the centre of a small pulmonary nodule in.

Pathogenesis of idiopathic pulmonary fibrosis (IPF).

3-year survival of lung cancer patients in the general population and in those with a prior diagnosis of chronic obstructive pulmonary disease (COPD).

Multimodal management of a central airway obstruction by a squamous cell carcinoma using laser and temporary carinal stent placement, followed by radiation.

Immune reconstitution inflammatory syndrome (IRIS) associated with Mycobacterium tuberculosis (TB) infection. a) In healthy individuals in response to.

A summary of the pathogenesis, pathophysiology and clinical implications of the pulmonary vascular and cardiac abnormalities in interstitial lung disease.

Time to disease progression or death in a) the whole Bosentan Use in Interstitial Lung Disease (BUILD)-1 study population and b) the subpopulation with.

Evaluation of complications.

Histological examination (Haematoxylin-eosin staining) of the pulmonary aspergilloma. a) A dilated bronchus filled with necrosed aspergillus hyphae. Histological.

Proteinase activated receptor-1 expression in a) weak immunostaining in normal lung tissue, b) intense immunostaining in idiopathic pulmonary fibrosis,

Proposed mechanisms for fibrointimal proliferation in pulmonary tumour thrombotic microangiopathy (PTTM). Proposed mechanisms for fibrointimal proliferation.

Change in forced vital capacity (FVC) % predicted (% pred) per week from baseline in the CAPACITY 004 and 006 study comparing pirfenidone (2403 mg·day−1)

Nat. Rev. Urol. doi: /nrurol

Mechanisms of virus-induced airway inflammation in chronic obstructive pulmonary disease (COPD). Mechanisms of virus-induced airway inflammation in chronic.

Established and putative mediators and pathways involved in the pathogenesis of pulmonary arterial hypertension. Established and putative mediators and.

Significance of the principal genetic variants associated with familial pulmonary fibrosis by their strength and frequency. Significance of the principal.

Pulmonary angiography in the right lung (a, c, e and g) and the left lung (b, d, f and h) of a patient with chronic thromboembolic pulmonary hypertension.

Outline of the distal lung regions in haematoxylin and eosin-stained lung tissue [115, 116] showing the inner airway wall (green arrowheads), smooth muscle.

Transbronchial cryobiopsy (TBCx)

Molecular pathways underlying angiogenesis.

Forest plot of the a) sensitivity and b) specificity of different pulmonary function test screening algorithms for the presence of systemic sclerosis-associated.

This schematic view of the morpho-functional unit of the lung (alveolus) depicts the main differences in cellular composition in idiopathic pulmonary fibrosis.

Involvement of matrix metalloproteinases (MMPs) and interleukin (IL)-8 during human airway epithelial regeneration in the nude mouse xenograft model. Involvement.

Protease/anti-protease imbalance and oxidative stress are viable pro-inflammatory mechanisms that contribute to the pathogenesis of chronic obstructive.

A) Small pulmonary arteries within a fibrotic area (usual interstitial pneumonia lung). a) Small pulmonary arteries within a fibrotic area (usual interstitial.

A) Conventional pulmonary angiogram, with b) and c) corresponding optical coherence tomography images from a patient with chronic thromboembolic pulmonary.

Proportion of participants with access to a, b) a radiologist and c, d) a pathologist experienced in interstitial lung diseases to discuss cases of suspected.

A) Annual diagnosed incidence of pulmonary embolism (PE), and b) annual full incidence of chronic thromboembolic pulmonary hypertension (CTEPH) per 100 000.

Fibroblast responses to changes in miR-21-5p and miR-29 family levels

Forest plot from meta-analysis carried out on four studies including high-dose N-acetylcysteine (NAC) treatment a) assessing the relative risk of chronic.

Correlation between inspiratory capacity (IC)/total lung capacity (TLC) ratio and oxygen pulse at peak exercise in chronic obstructive pulmonary disease.

Expression of genes related to inflammasome activation in peripheral blood mononuclear cell (PBMC) and bronchoalveolar lavage (BAL) macrophages. Expression.

Clinical findings in patients with chronic obstructive pulmonary disease according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD)

Procedure for the diagnosis of interstitial lung diseases.

Progression in the patient’s pulmonary function tests from 2010 to a) Forced vital capacity (FVC); b) total lung capacity (TLC); c) diffusing capacity.

Investigation of suspected idiopathic pulmonary fibrosis: multidisciplinary team (MDT) discussion is a key component of the diagnostic pathway. Investigation.

Bronchial biopsy from patient 5 (a; Haematoxylin-Eosin-Safran stain and ×10 growth). Bronchial biopsy from patient 5 (a; Haematoxylin-Eosin-Safran stain.

Distribution and change of the underlying disease in patients discharged with home mechanical ventilation (n = 854). ♦: chronic obstructive pulmonary disease;

Cellular players and molecules in idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-associated interstitial lung disease. Cellular players and.

Pathogenic concepts of pulmonary arterial hypertension (PAH).

Hyperplastic alveolar epithelial type II cells show severe endoplasmic reticulum stress and consecutive apoptosis. Hyperplastic alveolar epithelial type.

Pulmonary artery pressure in a) healthy subjects and b) pulmonary hypertension (PH) subjects. Pulmonary artery pressure in a) healthy subjects and b) pulmonary.

Interventional bronchoscopic and surgical treatments for chronic obstructive pulmonary disease (COPD). Interventional bronchoscopic and surgical treatments.

Lung macrophage development and composition through the lifespan.

Differential pathway regulation in advanced idiopathic pulmonary fibrosis (IPF) lung. a) Metacore analyses of pathway enrichment in IPF versus control.

Schematic diagram of the potential cellular effects of interleukin (IL)-4/IL-13 on inflammatory and structural cells in asthma. Schematic diagram of the.

High-resolution computed tomography images of smoking-related interstitial lung diseases (ILDs). a) Pulmonary Langerhans cell histiocytosis, b) respiratory.

A) Chest computed tomography image showing left upper lobe cavitary lesion consistent with invasive pulmonary aspergillosis (IPA) in an allogeneic haematopoietic.

Fig. 5. Effects of IL-9 blockade on chronic pulmonary inflammation

Effect of placebo (n=88) and bosentan (n=80) on the co-primary end-point pulmonary vascular resistance (PVR) in the EARLY (Endothelial Antagonist Trial.

The natural history of chronic obstructive pulmonary disease (COPD) is a mixture of the natural history of the various phenotypes making up the umbrella.

Presentation transcript:

The antifibrotic activity of pirfenidone in preclinical models of pulmonary fibrosis. a) Experimental design and effects of prophylactic pirfenidone treatment on bleomycin-induced pulmonary fibrosis [38]. b) Effects of delayed pirfenidone treatment on bleom... The antifibrotic activity of pirfenidone in preclinical models of pulmonary fibrosis. a) Experimental design and effects of prophylactic pirfenidone treatment on bleomycin-induced pulmonary fibrosis [38]. b) Effects of delayed pirfenidone treatment on bleomycin-induced pulmonary fibrosis (H. Oku, Shionogi and Co. Ltd, Osaka, Japan; personal communication). c) Effects of prophylactic pirfenidone treatment on bleomycin-induced pulmonary fibrosis [44]. d) Experimental design and effects of pirfenidone in an orthotopic lung transplant model [45]. e) The effects of pirfenidone in a mouse model of airway remodelling and hyperresponsiveness induced by sensitisation and challenge with ovalbumin [47]. BAL: bronchoalveolar lavage; bFGF: basic fibroblast growth factor; IL: interleukin; IFN: interferon; OVA: ovalbumin; PDGF: platelet-derived growth factor; SD: Sprague-Dawley; SDF: stromal cell-derived factor; TGF: transforming growth factor. C.J. Schaefer et al. Eur Respir Rev 2011;20:85-97 ©2011 by European Respiratory Society